| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 11, 2026 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2025 | $9.00 | Buy | H.C. Wainwright |
| 1/28/2025 | $9.00 | Buy | Guggenheim |
| 5/13/2022 | $25.00 → $15.00 | Overweight | Cantor Fitzgerald |
| 11/24/2021 | $35.00 → $25.00 | Buy | HC Wainwright & Co. |
SCHEDULE 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
10-Q - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
H.C. Wainwright resumed coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $9.00
Guggenheim initiated coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $9.00
Cantor Fitzgerald resumed coverage of Eledon Pharmaceuticals with a rating of Overweight and set a new price target of $15.00 from $25.00 previously
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the submission of a Pre-Investigational New Drug ("Pre-IND") briefing package to the U.S. Food and Drug Administration ("FDA") to support the proposed First-In-Human ("FIH") clinical trial of NCEL-101 in combination with tegoprubart, an investigational immunomodulatory agent being developed by Eledon Pharmaceuticals (("Eledon", NASDAQ:ELDN). The submission represents a significant mi
IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster presentation at the American Transplant Congress (ATC) taking place in Boston, MA from June 20-24, 2026. Results will include updated data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study. Details on the presentations are below: Oral Presentation Title: Phase 2 BESTOW Trial: Evaluating Tegoprubart's Safety and Efficacy in Preventing Kidney Transplant Rejection Presenter: A
100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study FDA Orphan Drug designation granted to tegoprubart for the prevention of allograft rejection in liver transplantation Cash, cash equivalents and short-term investments totaled $111.1 million as of March 31, 2026 IRVINE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its first quarter 2026 operating and financial results and provided recent business highlights. "In the first quarter of 2026, we achieved significant milestones in our tegoprubart program, including impo
IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster presentation at the American Transplant Congress (ATC) taking place in Boston, MA from June 20-24, 2026. Results will include updated data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study. Details on the presentations are below: Oral Presentation Title: Phase 2 BESTOW Trial: Evaluating Tegoprubart's Safety and Efficacy in Preventing Kidney Transplant Rejection Presenter: A
NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones Substantially debt free, NewcelX recently closed a financing of up to approximately $3.4 million, including $1.35 million in cash and approximately $2 million of potential additional proceeds from the exercise of warrants, and has access to up to a $25 million Equity Line of Credit Strengthened scientific leadership with appointment of Julien Boisdron, MD, Chief Medical Officer of a Swiss Big Pharma, to Scientific Advisory Board Aims to significan
Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m² Tegoprubart demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus Supports advancement into Phase 3 development as a potential new standard for the prevention of kidney transplant rejection Conference call to be held Friday, November 7 at 8:00 a.m. ET IRVINE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced results from it
Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human Additional data from 11 participants in Phase 1b trial in kidney transplantation demonstrated that tegoprubart was generally safe and well tolerated, successfully prevented rejection and permitted above historical average post-transplant kidney function IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its fourth quarter and full year 2023 opera
Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated Dosed first participants in Phase 2 BESTOW trial in kidney transplantation Tegoprubart dosed in second-ever pig to human xenotransplant procedure IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones. 2023 Key Highlights Reported updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection i
Reported updated data from ongoing Phase 1b trial further supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy to prevent rejection and better preserve organ function First participant dosed in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its third quarter operating and financial results and reviewed recent business highlights. "We were thrilled recently to report updated results from our ongoing Phase 1b study that continue to validate tegoprubart's potential as an immuno
SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)